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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a highly chemoresistant tumor entity for which no
reliable molecular targets exist to predict or influence the success of chemotherapy. Recently, we identified a panel
of microRNAs associated with induced gemcitabine chemoresistance in human PDAC cell lines. This clinical study
evaluates these microRNAs and associated molecular markers as prognostic markers of outcome in 98 PDAC patients
Union Internationale Contre le Cancer (UICC) stage II undergoing curative surgery with adjuvant gemcitabine
chemotherapy. The primary end points of this study are recurrence-free survival and overall survival.
Results: Poor response to chemotherapy was significantly correlated to overexpression of microRNA-21 (p = 0.029),
microRNA-99a (p = 0.037), microRNA-100 (p = 0.028), and microRNA-210 (p = 0.021) in tissue samples of PDAC patients
UICC stage II. Upregulation of these microRNAs was associated with a significantly shorter overall survival and
recurrence-free survival (p < 0.05). Overexpression of phosphatase and tensin homolog (PTEN) (p = 0.039) and
low expression of multidrug resistance (MDR)-1 (p = 0.043) and breast cancer resistance protein (BCRP)-1 (p = 0.038)
were significantly correlated to improved response to adjuvant chemotherapy. Adjuvant gemcitabine treatment
(p < 0.0001) and low tumor grading (p = 0.047) were correlated to better outcome. MicroRNA-100, microRNA-21,
and its targets PTEN and MDR-1 were independent factors of survival in multivariate analysis.
Conclusions: Multivariate survival analyses identified microRNA-21 and microRNA-100 as unfavorable prognostic
factors in resected and adjuvant treated PDAC UICC stage II patients.
Keywords: Pancreatic ductal adenocarcinoma, Chemoresistance, microRNA
Background
Pancreatic ductal adenocarcinoma (PDAC) remains one
of the most deadly cancers in western countries with a
median survival below 6 months and a dismal 5-year
overall survival rate of less than 5 % [1]. Despite devel-
opments in novel diagnostic and surgical techniques
over the past decades, only morbidity and postoperative
mortality were improved, without significant impact on
survival. Lack of early symptoms combined with rapid
disease progression result in low resectability rates of
about 15 % of PDAC patients with 5-year survival rates
below 20 % [2].
Adjuvant first-line chemotherapy and palliative treat-
ment by gemcitabine have slightly improved the clinical
outcome. However, nearly half of the treated patients do
not benefit from gemcitabine-based therapies [3, 4].
Chemotherapy response markers are needed to identify
PDAC patients who may benefit from adjuvant gemcita-
bine chemotherapy.
PDAC chemoresistance is acquired through multiple
molecular pathways and genetic alterations affecting cell
cycle, apoptosis, and intracellular drug accumulation.
Especially, members of the ATP binding cassette
(ABC) superfamily including multidrug resistance
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(MDR)-1 P-glycoprotein, multidrug resistance protein
(MRP)-1, and breast cancer resistance protein (BCRP)-1
have been shown to mediate resistance against several
anticancer drugs by enhanced drug efflux across cellular
plasma membranes [5]. Deoxycytidine kinase (DCK), a
key activator of gemcitabine, and its regulator Hu antigen
R (HuR) have been identified as powerful independent
prognostic factors for PDAC patients undergoing adjuvant
gemcitabine therapy [6–8]. Further, mutations and epigen-
etic downregulation of phosphatase and tensin homolog
(PTEN), a tumor suppressor and the most important
negative regulator of Akt/PI3K signaling, are regarded as
crucial for PDAC development and chemoresistance [9].
Although a number of molecular players have been
connected to chemoresistance, their clinical impact re-
mains controversial [10].
We previously identified a panel of microRNAs associ-
ated with induced gemcitabine chemoresistance in hu-
man PDAC cell lines: Two PDAC cell lines were treated
by repeated pulsatile gemcitabine treatment to induce
acquired chemoresistance. Global microRNA profiling
identified a panel of 16 significantly and concordantly
dysregulated microRNAs in both chemoresistant PDAC
cell clones [11].
In this clinical study, our aim was to validate these
microRNA candidates as prognostic markers of chemo-
therapy response to gemcitabine in patients with resected
PDAC stage II according to the Union Internationale
Contre le Cancer (UICC).
Results
Clinicopathologic factors and chemotherapy response as
survival markers
A total of 91 PDAC patients UICC stage II with curative
pancreatic head (82.4 %) or left resection (17.6 %) and
13 patients with benign, noninflammatory pathology
were analyzed (Table 1). Seven of initially 98 PDAC pa-
tients with an in-hospital-mortality of ≤30 days were ex-
cluded. The median age at diagnosis was 66 years, and
the male to female ratio was approximately 1.2:1. The
distribution by stage was 31.9 % UICC stage IIa and
68.2 % Stage IIb. The majority of patients (65; 71.4 %)
had died by the time of final analysis with a median
follow-up time of 30.5 months for the 26 patients still
alive. The median survival time for all patients was
22 months.
Univariate analyses indicated that tumor grading
(p = 0.0474) correlated with worse overall survival.
Patients who underwent adjuvant gemcitabine chemother-
apy had significantly improved overall survival rates
(p = 2.9922E-8) (Table 1). Patients with adjuvant gem-
citabine treatment and good response (determined by
median split) showed improved median overall and
recurrence-free survival vs. bad response (33 months,
95 % confidence interval (CI) 26–49 vs. 19 months,
95 % CI 15–13, p = 1.3628E-09 and 32 months, 95 %
CI 25–46 vs. 11 months, 95 % CI 8–12, p = 2.8043E-15)
and vs. no adjuvant treatment (12 months, 95 % CI 8–17,
p = 9.0791E-13 and 7 months, 95 % CI 5–9, p = 1.565E-15).
Improved overall survival was even shown in patients
with poor chemotherapy response vs. no adjuvant
treatment (p = 0.0093) (Fig. 1). Subgroup analysis of





95 % CI p
Total 91 21 16–26
Age (years)
≤65 41 27 21–33 0.1754
>65 50 19 16–22
Gender
Female 41 26 18–34 0.8796
Male 50 20 15–25
UICC stage
IIa 29 27 13–40 0.3347
IIb 62 20 16–24
Grading
G1 and G2 55 26 1–31 0.0474
G3 36 15 8–22
Perineural invasion
Pn0 32 19 9–29 0.7835
Pn1 59 21 16–26
Vene invasion
V0 74 23 16–30 0.5583
V1 17 21 17–25
Lymphatic invasion
L0 50 24 18–29 0.9821
L1 41 21 15–26
Resection margin
R0 77 23 15–31 0.3653











Yes 64 31 24–37 2.9922E-8
No 27 12 9–14
Indication of median overall survival in months and 95 % confidence interval
(CI). p < 0.05 indicates significance
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response to chemotherapy groups (group II vs. III) re-
vealed no significant differences in the distribution of
clinicopathologic factors (Table 2).
MicroRNAs as markers of chemotherapy response and
survival
Macrodissected PDAC tissue of patients with poor (n = 39)
and good chemotherapy response (n = 25) was evaluated by
quantitative real-time PCR (qRT‐PCR) for the expres-
sion of in vitro chemoresistance-specific microRNAs (Fig. 2,
Table 3). MicroRNA-21 (p = 4.3817E-07), microRNA-31
(p = 0.0003), microRNA-99a (p = 0.0406), microRNA-100
(p = 4.0492E-08), microRNA-125b (p = 0.0001), microRNA-
138 (p = 0.0301), microRNA-147b (p = 0.0028), and
microRNA-210 expression (p = 0.0044) were significantly
upregulated in PDAC stage II vs. benign controls. Further,
microRNA-148 was significantly downregulated in PDAC
tissues (p = 3.9814E-09).
Expression of in vitro dysregulated microRNA-376a,
microRNA-330-3p, microRNA-330-5p, microRNA-378d,
microRNA-422a, microRNA-455-3p, and microRNA-
486-5p did not differ between PDAC and control.
After normalization to benign noninflammatory con-
trols (n = 13) by the ΔΔCt method, poor adjuvant gemci-
tabine mono-chemotherapy response was significantly
related to overexpression of microRNA-21 (p = 0.0366),
microRNA-99a (p = 0.0163), microRNA-100 (p = 0.0157),
and microRNA-210 (p = 0.0252) (Fig. 3).
Kaplan-Meier survival analysis revealed significantly im-
proved overall survival and recurrence-free survival rates
in PDAC patients with low expression of microRNA-21
(cutoff 4.7; p = 0.0181; p = 0.0149), microRNA-99a (cutoff
2.5; p = 0.0325; p = 0.1711), microRNA-100 (cutoff 5.0;
p = 0.0004; p = 0.0111), microRNA-125b (cutoff 1.6;
p = 0.0491; p = 0.0373), and microRNA-210 (cutoff
4.6; p = 0.0161; p = 0.0116) in the adjuvant setting
(Fig. 4). Univariate Cox regression overall and recurrence-
free survival analyses identified microRNA-21 (p = 0.0231;
p = 0.0211), microRNA-99a (p = 0.0393; p = 0.1864),
microRNA-100 (p = 0.0013; p = 0.0163), microRNA-125b
(p = 0.0578; p = 0.0472), and microRNA-210 (p = 0.0211;
p = 0.0168) as unfavorable prognostic factors in resected
and adjuvant-treated PDAC UICC stage II patients
(Table 5). These microRNAs did not correlate significantly
with standard clinicopathologic parameters or immuno-
histological markers (data not shown).
Classic immunohistological PDAC chemoresistance und
survival markers
Corresponding formalin-fixed paraffin-embedded (FFPE)
sections of our study groups with 91 patients with
PDAC UICC stage II and 13 patients with pancreatic
cystadenoma or papillary adenoma (total n = 104) were
evaluated immunohistochemically by tissue microarray
for the expression of the tumor suppressor PTEN, the
gemcitabine metabolism regulators DCK and HuR, and
the ATP transporters MDR-1, MRP-1, and BCRP-1, as
well as the tumor angiogenesis marker vascular epithe-
lial growth factor (VEGF)-1. MDR-1 (p = 0.0426) and
BCRP-1 (p = 0.0378) overexpression as well as PTEN
(p = 0.0394) underexpression correlated significantly with
poor chemotherapy response in PDAC patients. VEGF-1
was significantly downregulated in PDAC tissue vs. benign
controls (p < 0.0001) (Fig. 5, Table 4).
Kaplan-Meier survival analysis revealed significantly
improved overall survival and recurrence-free survival
rates in PDAC patients with high expression of PTEN
(p = 0.0007 each) and low expression of MDR-1 (p =
0.0163; p = 0.0015) and BCRP-1 (p = 0.0047; p = 0.00003)
in the adjuvant setting (Fig. 6). Univariate Cox regression
Fig. 1 Prognostic impact of adjuvant gemcitabine treatment in PDAC UICC stage II patients. Improved overall (a) and recurrence-free survival (b)
in patients with adjuvant gemcitabine treatment and good (n = 25) vs. bad (n = 39) response (p = 1.3628E-09; p = 2.8043E-15) and vs. no adjuvant
gemcitabine treatment (n = 27) (p = 9.0791E-13; p = 1.565E-15). Improved overall survival in patients with bad chemotherapy response vs.
no adjuvant treatment (p = 0.0093)
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Table 2 Clinicopathologic characteristics of PDAC patients UICC stage II with different adjuvant chemotherapy response
Total PDAC II
w/o CTX
PDAC II w CTX P P
Good response Bad response
(n = 91) I (n = 27) II (n = 25) III (n = 39) II vs. III
Age (years)
≤65 41 10 12 19 0.5092 1
median (range) 63 (54–65) 56 (41–64) 53 (31–65)
>65 50 17 13 20
median (range) 72 (66–84) 73 (66–84) 71 (67–79)
Gender
Female 41 14 11 16 0.6801 1
Male 50 13 14 23
UICC stage
IIa 29 7 9 13 0.6469 1
IIb 62 20 16 23
Grading
G1 5 0 3 2 0.0231 0.5008
G2 50 10 16 24
G3 36 17 6 13
Perineural invasion
Pn0 32 10 10 12 0.7305 0.5904
Pn1 59 17 15 27
Vene invasion
V0 74 23 22 29 0.3256 0.2204
V1 17 4 3 10
Lymphatic invasion
L0 50 17 15 18 0.3367 0.3149
L1 41 10 10 21
Resection margin
R0 67 20 21 26 0.3071 0.1553
R1 24 7 4 13
Type of surgery
Pancreatic head resection 75 26 17 32 0.0276 0.2347
Traverso-Longmire 66 22 15 29
Whipple-Kausch 9 4 2 3
Pancreatic left resection 16 1 8 7
Adjuvant gemcitabine
Yes 64 0 25 39 0.0000 1
No 27 27 0 0
Tumor recurrence
≤18 months 63 24 0 39 0.0000 0.0001
>18 months 5 2 3 0
Tumor related death
≤18 months 39 20 0 19 0.0234 0.0856
>18 months 22 6 3 13
p < 0.05 indicates significance
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overall and recurrence-free survival analyses identified
PTEN (p = 0.0014; p = 0.0015) and DCK (p = 0.0939;
p = 0.0345) as favorable prognostic factors as well as
MDR-1 (p = 0.0208; p = 0.0028), BCRP-1 (p = 0.0074;
p = 0.0001), and MRP-1 (p = 0.0576; p = 0.0049) as
unfavorable prognostic factors in resected and adjuvant-
treated PDAC UICC stage II patients (Table 5).
Identification of independent prognostic factors by
multivariate analysis
Multivariate Cox regression overall and recurrence-free
survival analyses identified microRNA-21 (p = 0.0064;
p = 0.0338), microRNA-100 (p = 0.0045; p = 0.1683), and
MDR-1 (p = 0.0003; p = 0.0021) as unfavorable prognostic
factors while PTEN (p = 0.1008; p = 0.0211) was a favorable
Fig. 2 ΔCT expression level (means with standard deviation) of in vitro chemoresistant-specific microRNAs in benign and cancerous human
pancreatic specimen. ΔCt levels are inversely proportional to the amount of target microRNA in the sample. Asterisk indicates to a significant
difference of p< 0.05 between PDAC patients with good and poor chemotherapy (w CTX) response. Number sign and section sign indicate to a significant
difference of p< 0.05 between benign noninflammatory pancreas controls and PDAC with good or bad CTX response, respectively
Table 3 MicroRNA expression of PDAC patients with good and poor chemotherapy (w CTX) response
Control vs. PDAC w CTX good response Control vs. PDAC w CTX bad response PDAC w CTX good response vs. PDAC
w CTX bad response
microRNA-21 2.89 vs. 1.39 (+51.6 %)
p = 4.3817E-07
2.89 vs. 0.86 (+70.3 %)
p = 3.3364E-09
1.39 vs. 0.86 (+38.7 %)
p = 0.0295
microRNA-31* 15.02 vs. 12.74 (+15.2 %)
p = 0.0003
15.02 vs. 12.10 (+19.4 %)
p = 1.3354E-05
12.74 vs. 12.10 (+5.0 %)
p = 0.2232
microRNA-99a 6.23 vs. 5.61 (+10.0 %)
p = 0.0406
6.23 vs. 5.09 (+18.4 %)
p = 0.0004
5.61 vs. 5.09 (+9.3 %)
p = 0.0370
microRNA-100 6.91 vs. 5.18 (+25.0 %)
p = 4.0492E-08
6.91 vs. 4.69 (+32.2 %)
p = 2.9936E-11
5.18 vs. 4.69 (+9.5 %)
p = 0.0275
microRNA-125b 3.34 vs. 2.57 (+22.9 %)
p = 0.0001
3.34 vs. 2.31 (+30.8 %)
p = 0.0001
2.57 vs. 2.31 (+10.2 %)
p = 0.1968
microRNA-138 13.08 vs. 12.19 (+6.8 %)
p = 0.0301
13.08 vs. 11.95 (+8.7 %)
p = 0.0082
12.19 vs. 11.95 (+2.0 %)
p = 0.4705
microRNA-147b 14.57 vs. 13.44 (+7.8 %)
p = 0.0028
14.57 vs. 13.49 (+7.4 %)
p = 0.0105
13.44 vs. 13.49 (−0.4 %)
p = 0.8662
microRNA-148a 0.69 vs. 5.03 (−622.1 %)
p = 3.9814E-09
0.69 vs. 5.29 (−660.5 %)
p = 2.1259E-12
5.03 vs. 5.29 (−5.3 %)
p = 0.5821
microRNA-210 9.17 vs. 8.26 (+9.9 %)
p = 0.0044
9.17 vs. 7.56 (+17.6 %)
p = 4.9353E-05
8.26 vs. 7.56 (+8.5 %)
p = 0.0208
microRNA-376a 16.39 vs. 15.82 (+3.5 %)
p = 0.1332
16.39 vs. 15.28 (+6.8 %)
p = 0.0026
15.82 vs. 15.28 (+3.4 %)
p = 0.0849
Benign, noninflammatory pancreatic specimens of patients with pancreatic cystadenoma or papillary adenoma served as controls. All data are given as median
ΔCt level expression differences in percent. p < 0.05 indicates significance
Dhayat et al. Clinical Epigenetics  (2015) 7:132 Page 5 of 15
prognostic factor in resected and adjuvantly treated PDAC
UICC stage II patients (Table 6). As combinations of
microRNAs are likely to provide more accurate prog-
nostic information, the most accurate subset of vari-
ables (microRNA-21, -31*, -99, -100, -125b, -138,
-147b, -148a, -210, and -376a) was identified using
multivariate survival analysis with a forward stepwise
variable selection procedure based on the likelihood
ratio. Co-expression of microRNA-21 and microRNA-
100 as remaining independent prognostic factors re-
sults in a hazard ratio of 2.620 (95 % CI 1,251-5,487)
and 3.543 (95 % CI 1.504-8.345), respectively.
Discussion
As pancreatic cancer surgery and perioperative treat-
ment have significantly improved over the past decades,
today, resistance to chemotherapy and chemotoxicity re-
main as important aspects of treatment failure in resect-
able PDAC patients.
The high mortality of locally advanced and metastatic
PDAC could be reduced by increasing susceptibility to
adjuvant gemcitabine chemotherapy. Currently, no tissue
biomarkers are available to guide therapeutic strategies
or predict prognosis and chemotherapy response in
PDAC patients.
Several prognostic clinical factors of survival have been
identified in PDAC patients [12, 13]. In accordance with
the literature, low tumor grading and adjuvant gemcita-
bine chemotherapy were correlated to improved survival
in PDAC UICC stage II patients in this study. However,
with the exception of adjuvant gemcitabine treatment,
none of the investigated clinicopathological parameters
were independent prognostic markers in the adjuvant set-
ting. Instead, we identified microRNA-100 and microRNA-
21 with its targets PTEN and MDR-1 as independent
prognostic survival and chemotherapy response markers
in PDAC UICC stage II patients.
The oncogenic role of microRNA-21 in PDAC patients
and its association with poor survival and induction of
chemoresistance to gemcitabine is already well known
[9, 14]. Increased microRNA-21 expression has been
shown to promote chemoresistance through repression
of the tumor suppressor PTEN and decreased expression
of programmed cell death 4 (PDCD4). Interestingly, de-
crease in PDCD4 levels in turn increases the expression
of apoptosis inhibitors and the multidrug resistance pro-
tein MDR-1 [15–17]. In this study, high expression of
PTEN and low expression of MDR-1 was accompanied
by significantly improved overall and recurrence-free
survival as well as chemotherapy response. However, the
Fig. 3 The 2-ΔΔCt expression level of microRNA-21 (a), microRNA-99a (b), microRNA-100 (c), and microRNA-210 (d) in PDAC UICC stage II with
good and bad response. p < 0.05 indicates significance
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Fig. 4 Prognostic impact of microRNA-21 (a, b), microRNA-99a (c, d), microRNA-100 (e, f), microRNA-125b (g, h), and microRNA-210 (i, j) on overall
survival (right column) and recurrence-free survival (left column) in PDAC UICC stage II patients. p < 0.05 indicates significance
Dhayat et al. Clinical Epigenetics  (2015) 7:132 Page 7 of 15
clinical significance of MDR-1 expression in human
PDAC is controversial. Some research groups failed to
demonstrate MDR-1 expression in PDAC tissues, whereas
other studies showed a common and high MDR-1 expres-
sion potentially contributing to the chemoresistant biology
of PDAC [5, 18–21]. VEGF has been reported as a tumor
angiogenesis marker in PDAC, positively correlating with
microRNA-21 expression [9, 22]. However, the signifi-
cance of VEGF in tumor neoangiogenesis and progression
in PDAC is still unclear. Literature on the prognostic
value of VEGF in PDAC shows conflicting findings, and
phase II–III clinical trials did not reveal any benefit from
combined gemcitabine anti-VEGF PDAC treatment [23].
Our data could not confirm a prognostic role of
VEGF in PDAC.
We validated several microRNAs in clinical tumor
samples that we had previously identified to be dysregu-
lated in vitro [11]. The identified chemoresistance-
associated microRNAs 99a, 100, 125b, and 210 are
already known as potential oncogenes in PDAC. In
smaller clinical studies, microRNA-210 has been reported
to be overexpressed in PDAC patients and associated with
a worse outcome [24]. microRNA-99a and microRNA-
100, two members of the microRNA-99 family, were
found to be overexpressed in PDAC tissue compared with
normal pancreatic tissue and chronic pancreatitis [25].
Overexpression of microRNA-125b was demonstrated in
prostate cancer, glioblastoma, and drug resistance in
pediatric leukemia and breast cancer [26–29]. Inter-
estingly, co-overexpression of miR-125b, miR-99a, and
miR-100 was reported in different cancers suggests
possible co-regulation of these miRs in chemoresistant
PDAC as well [30, 31].
In addition to microRNA-21, microRNA-100 remained
as a further independant prognostic survival and chemo-
therapy response marker in multivariate analysis. Further
multi-center studies with a larger number of PDAC
patients are required to reevaluate the impact of
microRNA-99a, microRNA-125b, and microRNA-210
as independant survival predictors.
Fig. 5 Immunohistochemical staining of PTEN, MDR-1, und BCRP-1 in benigne pancreas (a, d, g), PDAC UICC stage II with good (b, e, h) and poor
chemotherapy response (c, f, i)
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Conclusions
We have identified a panel of microRNAs that could
serve as survival and chemotherapy response markers in
PDAC patients UICC stage II. In particular, microRNA-21
and microRNA-100 show promise as molecular markers




A tissue bank and follow-up database are maintained
prospectively by the Department of General and Visceral
Surgery and the Comprehensive Cancer Center Muenster,
University Hospital Muenster, Muenster, Germany. From
these, 98 PDAC UICC stage II tumor specimens having
Table 4 Immunohistochemical staining density of different study groups
Antibody Control (I) PDAC w CTX PDAC w/o CTX p
Good response (II) Bad response (III)
PTEN
+4 3 1 0 0 I vs. II: 0.0901
+3 6 7 6 0 I vs. III: 0.0003
+2 4 14 16 12 II vs. III: 0.0394
+1 0 3 17 15
DCK
+4 7 10 6 1 I vs. II: 0.7549
+3 4 8 13 16 I vs. III: 0.0287
+2 2 6 15 9 II vs. III: 0.1147
+1 0 1 5 1
HuR
+4 0 0 0 0 I vs. II: 0.0687
+3 5 2 3 1 I vs. III: 0.0137
+2 5 13 13 8 II vs. III: 0.3054
+1 3 10 23 18
MDR-1
+4 0 0 0 0 I vs. II: 0.7427
+3 0 1 7 1 I vs. III: 0.1068
+2 2 3 11 5 II vs. III: 0.0426
+1 11 21 21 21
MRP-1
+4 9 1 4 1 I vs. II: 0.00001
+3 4 3 12 3 I vs. III: 0.0001
+2 0 6 11 10 II vs. III: 0.1005
+1 0 15 12 13
BCRP-1
+4 2 0 0 0 I vs. II: 0.00003
+3 8 1 7 2 I vs. III: 0.0005
+2 3 12 24 19 II vs. III: 0.0378
+1 0 12 8 6
VEGF-1
+4 10 0 1 0 I vs. II: <0.0001
+3 3 4 6 2 I vs. III: <0.0001
+2 0 14 23 12 II vs. III: 0.8456
+1 0 7 9 13
p < 0.05 indicates significance
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Fig. 6 Prognostic impact of PTEN (a, b), MDR-1 (c, d), MRP-1 (e, f), and BCRP-1 (g, h) on overall survival (right column) and recurrence-free survival
(left column) in PDAC UICC stage II patients. p < 0.05 indicates significance
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undergone resection between 2003 and 2012 were
retrieved. Benign, noninflammatory pancreatic speci-
mens of 13 patients with pancreatic cystadenoma or
papillary adenoma served as controls. Tissue samples
were immediately fixed in 10 % buffered formalin and
then processed into a paraffin-embedded block and stored
at room temperature. Sections from each of the 111
specimens were examined by a pathologist and graded
histologically. All cancerous specimens showed vital
tumor tissue.
Table 5 Univariate Cox regression overall and recurrence-free survival analysis
Variable Subset Overall survival Recurrence-free survival
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
PTEN low/high 3.095 (1.5502–6.1805) 0.0014 2.7944 (1.4826–5.2669) 0.0015
DCK low/high 0.5536 (0.2772–1.1057) 0.0939 0.5178 (0.2813–0.9532) 0.0345
HuR low/high 0.6799 (0.3448–1.3409) 0.2656 0.6569 (0.3559–1.2125) 0.1789
MDR-1 low/high 2.2213 (1.1291–4.3698) 0.0208 2.5516 (1.3799–4.7179) 0.0028
MRP-1 low/high 2.0104 (0.9778–4.1331) 0.0576 2.5762 (1.3334–4.9773) 0.0049
BCRP-1 low/high 2.7438 (1.3117–5.7395) 0.0074 3.9656 (1.9563–8.0385) 0.0001
VEGF-1 low/high 1.5977 (0.6059–4.2123) 0.3435 1.3889 (0.6157–3.1331) 0.4286
N N0/N1 1.2670 (0.6269–2.5605) 0.5096 1.16965 (0.6213–2.2018) 0.6273
G G3/G1-2 0.9045 (0.4425–1.8491) 0.7833 0.7767 (0.4036–1.4946) 0.4492
L L0/L1 1.2793 (0.6478–2.5264) 0.4781 1.1996 (0.6541–2.1998) 0.5565
V V0/V1 1.4841 (0.6944–3.1716) 0.3083 1.7039 (0.8545–3.3975) 0.1301
Pn Pn0/Pn1 1.3512 (0.6629–2.7538) 0.4073 1.2389 (0.6426–2.3889) 0.5224
R 0/1 1.3996 (0.6839–2.8644) 0.3576 1.8921 (0.9923–3.6081) 0.0528
gender f/m 0.9404 (0.4784–1.8487) 0.8586 1.0039 (0.5444–1.8513) 0.9899
age >65/≤65 0.7334 (0.3747–1.4354) 0.3655 0.7598 (0.4142–1.3938) 0.3749
operation DP/PD 1.1089 (0.5034–2.4431) 0.7974 1.2319 (0.5889–2.5774) 0.5796
CTX response good/bad 23.3621 (5.5057–99.1321) 0.00002 159.7685 (11.1902–2281.0912) 0.0002
microRNA-21 low/high (2.3127) (1.1218–4.7675) 0.0231 2.2006 (1.1256–4.3022) 0.0211
microRNA-31* low/high 1.4769 (0.7365–2.9614) 0.2719 1.7738 (0.9362–3.3606) 0.0788
microRNA-99 low/high 2.2291 (1.0399–4.7781) 0.0393 1.5775 (0.8023–3.1019) 0.1864
microRNA-100 low/high 4.0097 (1.7189–9.3536) 0.0013 2.3653 (1.1714–4.7762) 0.0163
microRNA-125b low/high 2.1879 (0.9745–4.9127) 0.0578 2.0935 (1.0093–43426) 0.0472
microRNA-138 low/high 1.4770 (0.6583–3.3141) 0.3442 1.3268 (0.6556–2.6854) 0.4318
microRNA-147b low/high 0.8217 (0.4094–1.6489) 0.5805 0.7387 (0.3891–1.4022) 0.3543
microRNA-148a low/high 0.9135 (0.4533–1.8411) 0.8003 1.1714 (0.6249–2.1957) 0.6217
microRNA-210 low/high 2.4021 (1.1408–5.0578) 0.0211 2.2881 (1.1611–4.5091) 0.0168
microRNA-376a low/high 1.9456 (0.9518–3.9771) 0.0681 1.7029 (0.8906–3.2563) 0.1075
Indication of hazard ratio and 95 % confidence interval (CI). p < 0.05 indicates significance
Table 6 Multivariate Cox regression overall and recurrence-free survival analysis
Variable Subset Overall survival Recurrence-free survival
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
PTEN low/high 0.6076 (0.3351–1.1017) 0.1008 0.5431 (0.3232–0.9125) 0.0211
MDR-1 low/high 3.0434 (1.6602–5.5790) 0.0003 2.1309 (1.3164–3.4494) 0.0021
BCRP-1 low/high 0.7729 (0.3924–1.5225) 0.4565 1.3209 (0.7463–2.3378) 0.3394
microRNA-21 low/high 3.0649 (1.3709–6.8522) 0.0064 2.2521 (1.0640–4.7666) 0.0338
microRNA-100 low/high 4.8450 (1.6306–14.3961) 0.0045 1.8714 (0.7673–4.5643) 0.1683
microRNA-210 low/high 1.2116 (0.4849–3.0270) 0.6812 1.7623 (0.7634–4.0681) 0.1843
Indication of hazard ratio and 95 % confidence interval (CI). p < 0.05 indicates significance
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Ethical approval for postoperative tissue collection was
obtained (Ethics committee, University Muenster, Az:
1IXHai v. 19.9.2001), and all patients provided informed
written consent. All patients underwent radical resection
and were assigned to duodenopancreatectomy or left
pancreatic resection. Patients that received immunosup-
pression, neoadjuvant chemo-, or radiotherapy were
excluded to avoid potential influences on microRNA ex-
pression. Perioperative clinical data, histopathological in-
formation, and follow-up data were collected for all
patients using the clinical cancer registry. A poor chemo-
therapy response was defined as a tumor recurrence or a
tumor-related death of ≤18 months (cutoff) postopera-
tively. The cutoff of 18 months was selected due to the
median survival of 13–18 months of PDAC patients with
curative treatment intent (median split method) [32]. The
primary end points of this study were recurrence-free
survival and overall survival.
Tumor macrodissection and RNA purification
For each histological sample, a representative hematoxylin
and eosin (H&E)-stained section was reviewed by a
trained and experienced pathologist. Tissue samples in-
cluded in this study had >60 % viable cells and <20 % ne-
crosis. Tumor and stromal tissue areas were selectively
distinguished with a permanent marker by the pathologist
to guide macrodissection. Macrodissection of samples
with adenoma was carried out to create benign controls
using sample material distant from adenoma. Twenty-
micrometer sections from each FFPE tissue sample were
cut with a microtome and processed immediately. After
melting the paraffin block at 65 °C for 1 h to liberate the
tissue from the surrounding paraffin, separation of the
tumor tissue from the stromal area with a scalpel was
carried out. Cut sections were placed in 1.5 ml tubes
for RNA extraction.
Total RNA enriched in microRNAs fraction was puri-
fied through robotic workstation (QIAcube, Qiagen) by
using miRNeasy FFPE Kit isolation system following
manufacturer’s protocols (Qiagen). RNA concentration
and purity were assessed by Agilent 2100 Bioanalyzer and
RNA 6000 Nano/Pico LabChip (Agilent Tech., Boeblingen,
Germany). Samples with RIN >7 were considered intact
and used for analysis. RNA was stored at −80 °C.
Selection of microRNAs
Sixteen significantly deregulated microRNAs in two
human PDAC cell lines (MIA-PaCa-2 and PANC-1)
with acquired gemcitabine chemoresistance had been
previously identified. Our prior in vitro study with
Affymetrix GeneChip miRNA microarray (Affymetrix
UK Ltd., High Wycombe, UK) analysis of 1733 hu-
man microRNAs and validation by qRT-PCR showed
microRNA-21, microRNA-99a, microRNA-100, microRNA-
125b, microRNA-138, microRNA-147b, microRNA-148a,
microRNA-210, microRNA-376a, and microRNA-455-3p
to be significantly upregulated, whereas microRNA-31-star,
microRNA-330-3p, microRNA-330-5p, microRNA-378d,
microRNA-422a, and microRNA-486-5p were significantly
downregulated. Bioinformatic analysis and Western blot
validation suggested involvement of these microRNAs in
pathways controlling cell death and cycle [11].
MicroRNA expression data were normalized to ex-
pression levels of the four housekeeping genes RNU1A,
RNU6-2, SNORD68, and SNORD96A selected from a
total of ten tested housekeeping genes.
Quantification of microRNAs
qRT-PCR was performed using the miScript PCR system
(Qiagen). Total RNA samples (1 μg) were reverse tran-
scribed to complementary DNA (cDNA) using miScript
II Reverse Transcription Kit (Qiagen). For each sample,
2 μl of the generated cDNA was mixed with 10 μl 2×
QuantiTect SYBR, 2 μl 10× miScript Universal Primer,
2 μl gene specific 10× miScript Primer Assay (for five
different miRNAs), and 1 μl nuclease free water. All sam-
ples were analyzed in triplicate using Bio-Rad CFX384TM
RT PCR cycler (Bio-Rad Laboratories, Munich, Germany)
with miScript SYBR Green PCR Kit (Qiagen). No template
and minus RT controls were run in parallel. The cycling
program involved an initial incubation step of 15 min at
95 °C to activate HotStarTaq DNA Polymerase, followed
by 40 cycles of denaturation at 94 °C for 15 s, annealing at
55 °C for 30 s and elongation at 70 °C for 30 s.
Quantitative miR analysis was performed using CFX
Manager Software v2.1 (Bio-Rad Laboratories). Expression
of the selected microRNAs was analyzed quantitatively
relative to the four housekeeping genes (hg) by the 2–ΔΔCT
method using the equation: relative quantity R = 2–ΔΔCt,
where ΔΔCt = (Ct microRNA −Ct hg) cancer − (Ct micro-
RNA −CtT hg) benign and Ct is the cycle threshold [33].
Tissue array immunohistochemistry
For the tissue microarray (TMA), corresponding H&E-
stained sections from each FFPE block were used to
define and to mark representative tumor areas by the
pathologist, two to four random, representative 2-mm
tissue cores were punched from the designated area
using a biopsy needle and inserted in a grid pattern into
a recipient paraffin block using a tissue arrayer [34]. The
final TMA contained 44 tissue cores processed in dupli-
cate. Four-micrometer-thick sections were cut from each
completed TMA array block and transferred to silanized
glass slides. Sections from these arrays were then stained
with the panel of antibodies: phosphatase and tensin
homolog (PTEN) (monoclonal antibody, 1:200, clone
NCH-38, Dako, Hamburg, Germany), deoxycytidine kin-
ase (DCK) (monoclonal antibody, 1:5000, clone V9, Dako,
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Hamburg, Germany), HuR, MRP-1, MDR-1, BCRP-1,
VEGF-1, and lymphatic endothelial marker D2-40. These
antibodies were chosen based on their use as markers of
tumor suppression, gemcitabine transport, and metabol-
ism [5, 6, 8, 9, 35–37].
All immunohistochemical TMA studies were per-
formed by the avidin-biotin-peroxidase complex method
of Hsu et al. [38] For immunostaining, the Dako Auto-
stainer Plus S3400 and the Dako Real Detection System
(Alkaline Phosphatase/RED, Rabbit/Mouse, K5005) were
used according to the manufacturer’s instructions (Dako,
Hamburg, Germany). Briefly, after dewaxing and epitope
recovery for 35 min at 98 °C, endogenous peroxidase ac-
tivity was quenched by Dako Real Peroxidase-Blocking
Solution for 10 min at room temperature. Afterwards,
slides were incubated with primary antibodies and di-
luted in Dako Real antibody diluent, for 25 min. This
step was followed by incubation with Dako Real Link,
biotinylated secondary antibodies (20 min), incubation
with Dako Real Streptavidin Alkaline Phosphatase (20 min),
and visualization by RED chromogen (2 × 8 min) using the
Dako autostaining system with appropriate controls for
each run. Finally, slides were counterstained with Mayer’s
hematoxylin and dehydrated in graded alcohols. Positive
controls were included in all experiments using the same
experimental conditions. A negative control was prepared
by the same staining procedure without primary antibodies.
Immunohistochemical staining was evaluated semi-
quantitatively, according to the percentage of cells showing
specific immunoreactivity. Two independent investigators
evaluated, in a blinded manner, antibody staining using
light microscopy (Eclipse E1000M and NIS-Elements D3.1
imaging software, Nikon, Tokyo, Japan) and a scoring sys-
tem with a scale ranging from 0 to 4+ [5]. Disagreements
were resolved by joint review. For each case, the core with
the highest percentage of tumor cell staining was used for
analysis. Grade 0 was defined as complete absence of
staining. Grade 1+ was defined as a low positive stain-
ing up to 25 %. Grade 2+ was defined as a moderate
positive staining density of ≥25 but <50 %. A positive
high staining density ≥50 % but <75 % of cells was defined
as grade 3+. Finally, a positive staining density ≥75 % was
assessed as grade 4+. Staining intensity was scored as
weak, moderate, or strong.
Statistical analysis
Statistical analysis was performed with the SPSS® Statis-
tics Version 22 (IBM Corp. Armonk, NY) for Windows®.
Data were expressed as medians of mean normalized ex-
pression with standard deviation (SD). Statistical signifi-
cance was determined by using the two-tailed Student’s
ttest to compare two data sets.
Box-and-whisker plots demonstrating the median (mid-
dle quartile) were used to show normalized microRNA
expression data (2-ΔΔCt) in the different therapy response
groups. The middle half of a data set falls within the inter-
quartile range represented by the width of the box. The
whiskers indicate variability outside the upper and lower
quartiles. The grand mean representing the overall mean
of all data combined is displayed as a horizontal line
across the entire graph. Comparison between gene expres-
sion and categorical variables was conducted using the
nonparametric Mann-Whitney U test or the Kruskal-
Wallis test to test more than two groups. To test the
correlation between the clinicopathological data and the
expression of the microRNAs, we used the Fisher two-
tailed exact test and whenever appropriate the χ2 test. All
of the variables were dichotomized. For analysis of
follow-up data, life table curves were calculated using
the Kaplan-Meier method. Log-rank test was used for
comparison of relapse-free survival rates and survival rates
between the groups with high and low microRNA or
TAM marker expression in PDAC tissue compared to be-
nign controls. For the identification of the best cutoff
value for a supposed prognostic variable the log-rank test
was performed for all observed values within the entire
data set according to LeBlanc et al. [39] The primary end
points were disease-specific survival or relapse-free sur-
vival, as measured from the date of surgery to the time of
the last follow-up or cancer-related death or tumor re-
lapse, respectively. Data of patients who were still alive
and without evidence of tumor relapse at the end of the
study were censored. A Cox proportional-hazards regres-
sion model was used to estimate hazard ratios and 95 %
confidence intervals (CIs) and to perform multivariate sur-
vival analysis using a forward stepwise variable selection
procedure based on the likelihood ratio. Variables with
significant p values in the univariate analysis were in-
cluded in the multivariate analysis. p value <0.05 was con-
sidered to be statistically significant. Housekeeping gene
selection was performed by geNorm software (Biogazelle
NV, Zwijnaarde, Belgium), a popular algorithm to deter-
mine the most stable reference (housekeeping) genes from
a set of tested candidate reference genes (n = 10). The
gene expression stability measure (M) for a reference gene
is calculated by geNorm as the average pairwise variation
for that gene with all other tested reference genes. House-
keeping genes with an average expression stability M ≤ 0.5
were considered to have a high target reference stability
[40]. By this way, we identified four housekeeping genes
for accurate microRNA qRT-PCR data normalization.
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